We discuss the controversial FDA AdComm meeting for Biogen's aducanumab, a drug being developed to treat Alzheimer's disease.
Link to the FDA's website with AdComm materials: [ Ссылка ]
![](https://i.ytimg.com/vi/5a42X5XLygs/maxresdefault.jpg)
We discuss the controversial FDA AdComm meeting for Biogen's aducanumab, a drug being developed to treat Alzheimer's disease.
Link to the FDA's website with AdComm materials: [ Ссылка ]